Replimune Group (REPL) CMO sells 11,447 shares in tax-related transaction
Rhea-AI Filing Summary
Replimune Group, Inc. Chief Medical Officer Konstantinos Xynos reported a sale of 11,447 shares of common stock on 2026-08-10 at $12.97 per share. According to the disclosure, the shares were sold to cover tax withholding obligations upon vesting of performance-based RSUs under an irrevocable "sell to cover" provision and were not a discretionary sale. Following this transaction, Xynos directly holds 224,215 shares of Replimune common stock.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Seller: 11,447 shares
Net Sell
1 txn
Insider
Xynos Konstantinos
Role
Chief Medical Officer
Sold
11,447 shs ($148K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock F1 | 11,447 | $12.97 | $148K |
Holdings After Transaction:
Common Stock — 224,215 shares (Direct)
Footnotes (1)
- F1. Represents shares of the Issuer's common stock (the "Shares") sold to cover tax withholding obligations in connection with the vesting of the Reporting Person's performance-based restricted stock units (the "PSUs"). The transaction reported herein was made in accordance with the irrevocable "sell to cover" provision set forth in the award agreements under which the PSUs were granted and does not represent a discretionary sale by the Reporting Person.
Key Figures
Shares sold: 11,447 shares
Sale price per share: $12.97 per share
Shares owned after transaction: 224,215 shares
3 metrics
Shares sold
11,447 shares
Common stock sold on 2026-08-10 to cover tax withholding
Sale price per share
$12.97 per share
Price for the 11,447 common shares sold
Shares owned after transaction
224,215 shares
Direct common stock holdings of Konstantinos Xynos after the sale
Key Terms
sell to cover, performance-based restricted stock units, PSUs
3 terms
sell to cover financial
"The transaction was made in accordance with the irrevocable "sell to cover" provision"
Sell to cover is when a person who receives company stock through options or awards sells just enough shares immediately to pay required taxes, exercise costs, or fees, keeping the rest. Think of it like cashing part of a bonus to cover the tax bill so you can keep the remainder. For investors, it can create predictable small selling pressure and slightly change the number of shares actually held by insiders without increasing long‑term dilution.
performance-based restricted stock units financial
"in connection with the vesting of the Reporting Person's performance-based restricted stock units"
Performance-based restricted stock units are a type of employee equity award that converts into company shares only if predefined financial or operational targets are met over a set period. Think of it like a bonus check that becomes stock only when specific goals are hit; it ties pay to results, aligning managers’ incentives with shareholders. Investors care because these awards affect future share count, executive incentives, and signal how management’s success will be measured and rewarded.
PSUs financial
"under which the PSUs were granted and does not represent a discretionary sale"
PSUs are company shares promised to employees or executives that only become actual stock if the business hits specific performance targets over a set period. For investors, PSUs matter because they link pay to measurable outcomes — similar to a conditional bonus that converts into ownership — which can influence management decisions, dilution of shares, and signals about confidence in future results.
FAQ
What insider transaction did Replimune Group (REPL) report for Konstantinos Xynos?
Replimune’s Chief Medical Officer, Konstantinos Xynos, reported selling 11,447 shares of common stock on 2026-08-10 at $12.97 per share. The shares were sold to satisfy tax withholding obligations tied to vesting performance-based RSUs.
AI-generated analysis. How Rhea-AI works. Not financial advice.
